ABBV · 10-Q · 2026Q2 · Full report

Revenue Performance and Mix

AbbVie Inc. · 2026-08-03 · Importance 59 · Surprise 48 · No source text

Worldwide net revenues increased 11.2% to $31.992 billion for the six months ended June 30, 2026, or 9.9% on a constant-currency basis. U.S. revenue increased 9.6% to $23.830 billion, while international revenue increased 16.2% to $8.162 billion on a reported basis and 10.7% at constant currency. Skyrizi revenue rose 27.3% to $9.988 billion and Rinvoq revenue rose 24.0% to $4.644 billion for the six months, offsetting Humira’s 37.2% decline to $1.444 billion from biosimilar competition. Other significant six-month changes included Qulipta up 40.5%, Vyalev up more than 100%, Linzess up 42.1%, Imbruvica down 27.1%, and Juvederm Collection down 3.0%.

Key facts

• Worldwide net revenues for the six months ended June 30, 2026: $32.0 billion; increased 11% on a reported basis and 10% on a constant currency basis. source
• Skyrizi net revenues for the three months ended June 30, 2026: $5,505 million (24% increase at constant currency); for six months: $9,988 million (27.3% increase at actual, 26.3% constant). source
• Rinvoq total net revenues for the three months ended June 30, 2026: $2,525 million (24.5% increase at actual; 23.7% constant); for six months: $4,644 million (24.0% actual; 22.2% constant). source
• Net revenues by geographic region for the three months ended June 30, 2026: United States $12,861 million, International $4,129 million; total $16,990 million. source
• Net revenues by geographic region for the six months ended June 30, 2026: United States $23,830 million, International $8,162 million; total $31,992 million. source
• Vraylar net revenues increased 19% for the three and six months ended June 30, 2026. source

Impact estimates